Actively Recruiting
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
Led by Mayo Clinic · Updated on 2025-11-12
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
N
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating how changes in brain structure and function, seen through imaging, relate to the progression of speech, language, neurological, and psychological symptoms in people with neurodegenerative apraxia of speech (AOS). This disorder affects speech production and may occur alone or alongside a type of language difficulty called non-fluent aphasia (NFA). The study aims to understand disease progression and potential brain biomarkers using advanced imaging techniques. Participants will receive a Tau PET scan early in the study to measure Tau protein buildup in the brain, which is linked to neurodegeneration. The study applies advanced imaging methods including diffusion tensor imaging (DTI) and resting state functional MRI (fMRI) to explore brain connectivity and disease progression. These tools are being assessed for their ability to track changes over time in patients with AOS, with or without NFA. Throughout the study, participants will undergo repeated clinical assessments measuring speech, language, neurological, and neuropsychological function alongside imaging tests approximately 1 to 2 years after the initial scan. Researchers will compare changes in brain imaging with changes in clinical performance to better understand disease progression. Safety and eligibility will be monitored, and the study is expected to continue until mid-2028.
CONDITIONS
Brief Title
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with neurodegenerative apraxia of speech meeting clinical criteria at Mayo Clinic
- Adults aged 18 years or older
You will not qualify if you...
- Have other illnesses causing speech or language problems, such as traumatic brain injury, stroke, or developmental syndromes
- Are pregnant, recently gave birth, or currently breastfeeding
- Have contraindications to MRI, including metal implants or severe claustrophobia
- Have brain conditions that may affect imaging, like subdural hematoma or brain tumors
- Are medically unstable or taking medications affecting brain structure or metabolism
- Do not have an informant or do not consent to participate in research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 to 2 days
Participants undergo Tau PET scan to assess Tau burden in the brain.
1 visit (in-person) on approximately day 1 or day 2
Duration - Approximately 1 to 2 years
Participants are observed over approximately 1 to 2 years to assess longitudinal changes in neuroimaging and clinical performance.
Follow-up visits for imaging and clinical assessments over 1 to 2 years
Trial Site Locations
Total: 1 location
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
S
Sarah Boland, CCRP
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here